An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer

Drugs
Marie RobertMario Campone

Abstract

Deregulated cell division, resulting in aberrant cell proliferation, is one of the key hallmarks of cancer. Cyclin-dependent kinases (CDKs) play a central role in cell cycle progression in cancer, and the clinical development of the CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib has changed clinical practice in the setting of endocrine-receptor positive breast cancer. Results of pivotal phase II and III trials investigating these CDK4/6 inhibitors in patients with endocrine receptor-positive, advanced breast cancer have demonstrated a significant improvement in progression-free survival, with a safe toxicity profile. No validated biomarkers of sensitivity or resistance exist at the moment. Future development of CDK4/6 inhibitors in breast cancer should focus on the identification of predictive biomarkers, the development of drug combinations to overcome resistance, and the application of CDK4/6 inhibitors to other breast cancer subtypes.

References

Mar 1, 1994·Molecular and Cellular Biology·M Meyerson, E Harlow
Apr 24, 1997·Oncogene·L LamphereJ Gyuris
Feb 2, 1999·Oncogene·R J WieserF Oesch
Jul 1, 1999·Genes & Development·C J Sherr, J M Roberts
Jun 28, 2003·Proceedings of the National Academy of Sciences of the United States of America·Therese SorlieDavid Botstein
Jan 1, 2004·The Journal of Biological Chemistry·Qiang ZhaoKim T Arndt
Jan 18, 2006·Cancer Cell·Qunyan YuPiotr Sicinski
Apr 11, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Geoffrey I Shapiro
Oct 24, 2006·Cell·William Y Kim, Norman E Sharpless
Mar 16, 2007·Cell Cycle·Emily E Bosco, Erik S Knudsen
Feb 25, 2009·Nature Reviews. Cancer·Marcos Malumbres, Mariano Barbacid
Sep 9, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Christophe Le TourneauEric Raymond
Dec 24, 2010·Nature·Damien Coudreuse, Paul Nurse
Nov 18, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Keith T FlahertyGary K Schwartz
Sep 25, 2012·Nature·UNKNOWN Cancer Genome Atlas Network
Mar 5, 2013·Cold Spring Harbor Perspectives in Biology·Robert J Duronio, Yue Xiong
Apr 10, 2013·Trends in Cell Biology·Hirofumi HarashimaArp Schnittger
May 23, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sonya C TateDamien M Cronier
Jul 9, 2014·Cancer Cell·Sadhna R VoraJeffrey A Engelman
Dec 17, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Angela DeMichelePeter O'Dwyer
Apr 22, 2015·Nature Reviews. Clinical Oncology·Dimitrios ZardavasMartine Piccart
Jan 9, 2016·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Apr 1, 2016·Nature Reviews. Clinical Oncology·Ben O'LearyNicholas C Turner
Aug 6, 2016·Breast Care·Romualdo Barroso-SousaSara M Tolaney
Nov 1, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeffrey R InfanteGeoffrey I Shapiro

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

Expert Opinion on Investigational Drugs
Dimitrios ZardavasKonstantinos Tryfonidis
Nature Reviews. Clinical Oncology
Ben O'LearyNicholas C Turner
Journal of the National Comprehensive Cancer Network : JNCCN
William J Gradishar
© 2022 Meta ULC. All rights reserved